Polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-polymer based controlled release tablets of aceclofenac to simultaneously enhance the solubility and bioavailability

The aim of this study was to enhance the solubility of Aceclofenac with a new polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-polymer (Soloplus (R)) and formulate it in controlled release (CR) tablet dosage form by direct compression method with HPMC K-15. Solid dispersions were prepared in different ratio of Aceclofenac and Soloplus (R) as F-1, F-2 and F-3 with different polymer ratios i.e. 30%, 50%, and 70% respectively. All the quality control tests were performed for the prepared controlled release tablets. Drug polymer interaction studies of Aceclofenac and Soloplus (R) were carried using FTIR and XRD. Dissolution study was carried out against Alkaris (R) as a standard reference. The formulation F-3 showed optimum results and followed zero order kinetics. The Soloplus (R) improved the solubility of the drug and the CR formulation enhanced the delivery in a sustained manner. Hence, the CR formulation enhanced the delivery of aceclofenac in a sustained manner, thereby an efficient drug delivery may lead to an effective anti-inflammatory activity.

Automated summary

This study aimed to enhance the solubility of Aceclofenac with a new polymer Soloplus(R) and formulate it in controlled release tablets. Formulation F-3 showed optimal results, following zero order kinetics and improving drug solubility and sustained release. This controlled release formulation may lead to effective anti-inflammatory activity.